Financial Performance - The company's operating revenue for Q3 2023 was CNY 103,737,137.73, representing a year-on-year increase of 9.49% compared to CNY 94,741,694 in the same period last year[5] - Net profit attributable to shareholders for Q3 2023 reached CNY 15,415,838.98, a significant increase of 178.19% from CNY 5,541,534 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 15,208,864.41, up 139.11% from CNY 6,360,695 in the same period last year[5] - Basic earnings per share for Q3 2023 were CNY 0.06, a 200.00% increase from CNY 0.02 in the same period last year[5] - Net profit for Q3 2023 was CNY 13,004,310.86, a decrease of 45.3% compared to CNY 23,941,170.63 in Q3 2022[23] - Operating profit for Q3 2023 was CNY 13,924,282.32, down 46.1% from CNY 25,866,520.00 in the same period last year[23] - Total comprehensive income for Q3 2023 was CNY 13,004,310.86, a decrease of 45.3% from CNY 23,941,170.63 in Q3 2022[24] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was CNY 95,927,471, an increase of 34.95% compared to CNY 147,466,880 in the previous year[5] - Cash flow from operating activities in Q3 2023 was negative CNY 95,927,471.87, an improvement from negative CNY 147,466,884.77 in Q3 2022[26] - Cash flow from investing activities generated a net inflow of CNY 20,703,955.36 in Q3 2023, compared to CNY 189,463,645.32 in Q3 2022[26] - Cash and cash equivalents decreased to CNY 417,194,427.93 from CNY 506,315,013.83, representing a decline of 17.6%[18] - Cash and cash equivalents at the end of Q3 2023 were CNY 412,296,423.36, down from CNY 539,080,425.47 at the end of Q3 2022[26] - Total assets at the end of the reporting period were CNY 1,427,612,751.57, reflecting a decrease of 1.62% compared to the previous year-end[5] - Total assets as of September 30, 2023, were CNY 1,404,499,901.51, down from CNY 1,427,612,751.57, a decrease of 1.6%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,600[13] - The largest shareholder, Tongce Medical Co., Ltd., holds 19.01% of shares, totaling 49,920,315[13] - The top ten shareholders collectively hold significant stakes, with the largest being 19.01% and the smallest at 1.20%[13] - The total share capital as of the last trading day before disclosure was 262,560,141 shares[7] Liabilities and Equity - Total liabilities decreased to CNY 349,356,127.88 from CNY 386,019,066.98, a reduction of 9.5%[20] - The equity attributable to shareholders at the end of the reporting period was CNY 1,040,198,651.39, an increase of 1.26% from the previous year-end[5] - The total equity attributable to shareholders increased to CNY 1,053,314,646.12 from CNY 1,040,198,651.39, reflecting a growth of 1.3%[20] Operational Metrics - Total operating revenue for the third quarter of 2023 was CNY 282,449,005.28, a decrease of 6.5% compared to CNY 302,921,946.11 in the same period last year[22] - Total operating costs increased to CNY 267,340,257.60, up from CNY 261,258,375.67, reflecting a rise in operating costs by 2.1%[22] - Total revenue from sales of goods and services in Q3 2023 was CNY 212,287,538.88, an increase from CNY 185,279,514.21 in Q3 2022[25] Changes in Financial Position - Trading financial assets decreased by 57.07% to 30,111,402.78 due to reduced purchases of bank wealth management products[11] - Accounts receivable increased by 34.96% to 257,740,284.23, primarily due to increased sales collections[11] - Inventory rose by 64.11% to 87,098,810.21, attributed to certain project-related services already incurred but not yet recognized as revenue[11] - Development expenditures surged by 74.90% to 46,133,578.75, mainly due to ongoing capitalized R&D projects[11] - Financial expenses increased by 36.38% to -8,625,699.19, primarily due to increased interest income[11] - Investment income plummeted by 86.44% to 421,619.67, mainly due to reduced purchases of bank wealth management products[11] - Income tax expenses decreased by 68.53% to 629,987.35, reflecting a reduction in current tax expenses[11] Accounting and Reporting Changes - The company has implemented changes in accounting policies effective from January 1, 2023, impacting the financial statements[5] - The company has implemented new accounting standards starting from 2023[27] - The financial statement adjustments related to the first-time execution of the new accounting standards are applicable[27] - The third quarter report of Zhejiang Heren Technology Co., Ltd. has not been audited[27] - The report was released on October 23, 2023, by the board of directors[27] - There are no specific performance summaries or user data provided in the report[27] - Future outlook and performance guidance details are not included in the report[27] - Information regarding new product and technology development is absent[27] - Market expansion and acquisition strategies are not mentioned in the report[27] - Other new strategies are not discussed in the report[27]

证券代码：300550 证券简称：和仁科技 公告编号：2023-055 浙江和仁科技股份有限公司 1、金融资产 关于计提资产减值损失、信用减值损失的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"公司"）为真实、准确、客观反映 公司的财务状况和经营成果，根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》、《企业会计准则》等相关规定，公司本着谨 慎性原则，对合并财务报表范围内的各项需要计提减值的资产进行了评估和分 析，对预计存在可能发生减值损失的相关资产计提减值损失。现将相关情况公告 如下： 一、本次计资产减值损失、信用减值损失的情况概述 （一）、本次计提资产减值损失、信用减值损失的原因 根据《企业会计准则》和公司会计政策的相关规定，公司对合并范围内截止 2023 年 9 月 30 日的各类资产进行了清查、分析和评估，对部分可能发生信用、 资产减值的资产计提了减值损失。 （二）、本次计提资产减值损失、信用减值损失的情况 公司及下属子公司对 2023 年 9 月 30 日存在可能发生减值迹象的资 ...

深圳证券交易所文件 深证上〔2023〕893 号 关于对浙江和仁科技股份有限公司 及相关当事人给予通报批评的决定 当事人： 浙江和仁科技股份有限公司，住所：浙江省杭州市滨江区西 兴街道新联路 625 号； 杨一兵，浙江和仁科技股份有限公司时任董事长； 赵晨晖，浙江和仁科技股份有限公司总经理； 张雪峰，浙江和仁科技股份有限公司时任财务总监。 经查明，浙江和仁科技股份有限公司（以下简称和仁科技） 及相关当事人存在以下违规行为： 2023 年 4 月 27 日，和仁科技披露的《2022 年年度报告》显 示，报告期和仁科技实现归属于上市公司股东的净利润为亏损 8,330.64 万元。和仁科技未在 2022 年会计年度结束之日起一个 月内进行预告。 和仁科技的上述行为违反了本所《创业板股票上市规则 （2020 年 12 月修订）》第 1.4 条、第 6.2.2 条的规定。 和仁科技时任董事长杨一兵、总经理赵晨晖、时任财务总监 张雪峰未能恪尽职守、履行勤勉尽责义务，违反了本所《创业板 股票上市规则（2020 年 12 月修订）》第 1.4 条、第 4.2.2 条的规 定，对和仁科技的上述违规行为负有重要责任。 鉴于上述违 ...

1、浙江和仁科技股份有限公司（以下简称"公司"或"和仁科技"）本次回 购注销所涉及股份为 2017 股权激励计划中预留授予的部分股份，合计回购注销 6 名激励对象所持有的限制性股票 178,360 股，占公司回购前总股本的比例为 0.0679%，回购价格为 8.811953 元/股，同时公司根据《2017 年限制性股票激励 计划》的约定向激励对象支付了同期利息。 证券代码：300550 证券简称：和仁科技 公告编号：2023-053 浙江和仁科技股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次部分 限制性股票注销事宜已于 2023 年 9 月 14 日办理完成。 3、回购注销完成后，公司股份总数由 262,738,501 股减少为 262,560,141 股。 一、本次注销事项相关审批程序简述 1、2017 年 12 月 13 日，公司召开第二届董事会第五次会议，审议通过了《关 于公司 2017 年限制性股票激励计划（草案）及其摘要的议 ...

证券代码：300550 证券简称：和仁科技 公告编号：2023-052 注 册 资 本：贰亿陆仟贰佰伍拾陆万零壹佰肆拾壹元 成 立 日 期：2010 年 10 月 26 日 经 营 范 围：第二类：软件经营；第二类 6870 软件生产（生产地址详见 《医疗器械生产企业许可证》）。服务：软件开发，计算机软硬件、网络技术、系 统集成、机电一体化产品的技术开发、技术服务、技术咨询、成果转让，建筑智 能化工程的设计与施工（凭资质证书经营），自有房屋租赁，物业管理，第二类 增值电信业务。（依法须经批准的项目，经相关部门批准后方可开展经营活动） 浙江和仁科技股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司根据公司 2022 年年度股东大会的决议，对 2017 年限制性股票激励计划尚未解除限售的限制性股票进行回购注销，相应减少公司 总股本和注册资本，公司向浙江省市场监督管理局申请办理工商变更登记。近日， 公司收到由浙江省市场监督管理局核准换发的《营业执照》。变更后《营业执照》 登记的相关信息如下： 名 称：浙 ...

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 25% in the first half of 2023, reaching a total revenue of 500 million RMB[1]. - The company has set a revenue guidance for the second half of 2023, projecting an additional 20% growth, aiming for a total revenue of 600 million RMB by year-end[1]. - The company's revenue for the first half of 2023 was approximately ¥178.71 million, representing a decrease of 14.16% compared to ¥208.18 million in the same period last year[30]. - The net profit attributable to shareholders was a loss of approximately ¥2.30 million, a decline of 111.95% from a profit of ¥19.25 million in the previous year[30]. - The basic and diluted earnings per share were both reported at -¥0.01, a decline of 114.29% from ¥0.07 in the same period last year[30]. - The total operating revenue for the first half of 2023 was CNY 178.71 million, a decrease of 14.2% compared to CNY 208.18 million in the same period of 2022[173]. - The total profit for the first half of 2023 was -1,520,428.81 yuan, a significant decline from 23,951,971.46 yuan in the same period of 2022[179]. - The company reported a net profit margin of 7.5%, showcasing improved operational efficiency compared to the previous period[191]. User Engagement and Market Presence - User data indicates that the number of active users of the digital hospital solutions has grown by 30%, now totaling 1.2 million users[1]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next fiscal year through strategic partnerships with major healthcare institutions[1]. - The company is actively expanding its market presence with significant projects in Xi'an and Shaoxing, each valued over ¥10 million[45]. - The company has established long-term partnerships with major medical institutions across various provinces, enhancing its brand image and accumulating successful case studies in clinical information technology[67]. - The company plans to expand its market presence by launching new products in the second half of the year, targeting a 10% increase in market share[191]. Research and Development - The company has allocated 15% of its revenue towards R&D, focusing on innovative technologies in healthcare information systems[1]. - New product developments include an upgraded version of the clinical management information system, which is expected to enhance operational efficiency by 15% for clients[1]. - Research and development expenses increased by 2.63% to ¥33,198,624.21, compared to ¥32,349,035.12 in the same period last year[71]. - The company has initiated new product development strategies aimed at enhancing market competitiveness, although specific financial impacts were not disclosed[195]. - The company plans to enhance its product offerings and service capabilities in the medical information systems sector[200]. Financial Management and Investments - The company will not distribute cash dividends for the current fiscal year, opting to reinvest profits into growth initiatives[1]. - The company has not made any significant equity investments during the reporting period[85]. - The company has not undergone any changes in the use of raised funds for investment projects[93]. - The total amount of funds raised was RMB 49,631.96 million, with a cumulative investment of RMB 10,123.16 million as of the report date[88]. - The company has temporarily used 50 million yuan of idle raised funds to supplement working capital as of June 30, 2023[92]. Operational Challenges and Risks - The company is actively addressing risks related to client retention, implementing a new customer service strategy aimed at reducing churn by 5%[1]. - The company experienced a significant decline in operating income due to slower-than-expected recovery in customer demand, reflecting the cyclical nature of the industry[55]. - The company faces risks related to large system solution implementation, including project planning defects and key technology development failures[100]. - The company acknowledges potential uncertainties from changes in national policies and macroeconomic conditions affecting its operations[102]. Governance and Compliance - The company has a governance structure in place to protect shareholder rights and ensure compliance with relevant laws[115]. - The company has implemented measures to protect employee rights and promote their health and safety[115]. - The company reported no significant related party transactions during the reporting period[131]. - The company has maintained strong relationships with suppliers and customers, focusing on mutual growth and quality control[116]. Future Outlook - The company plans to focus on the development of "smart hospitals" and "digital health cities," launching new products and services based on digital platforms to create greater value for customers[60]. - The company is positioned to capitalize on the integration of digital technology in healthcare, enhancing service models and improving healthcare delivery efficiency[59]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[188].

单位：万元 浙江和仁科技股份有限公司 2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方 | 占用方与上 市公司的关 | 上市公司核 算的会计科 | 2023 年 期初 | 2023 年 1-6 月占用累计发 | 2023 年 1-6 月占 用资金的 | 2023 年 1-6 月偿 还累计 | 2023 年 6 月 末 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | 联关系 | 目 | 占用资金 余额 | 生金额 （不含利息） | 利息 | 发生金 | 占用资金余 额 | 原因 | | | | | | | | | （如有） | 额 | | | | | 控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | 小计 | - | | | | | | | | | - | | 前控股股东、实际控制人 及其附属企业 | | | | | | | ...

（二）、变更日期 公司根据上述会计准则解释规定，对会计政策进行相应变更，并按规定自 2023 年 1 月 1 日起执行。 浙江和仁科技股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"公司"）根据中华人民共和国财政 部（以下简称"财政部"）颁布的企业会计准则变更相应的会计政策，本次会计 政策变更无需董事会和股东大会审议。相关会计政策变更的具体情况如下： 一、本次会计政策变更的概述 （一）、会计政策变更原因说明 2022 年 11 月 30 日，财政部颁布了《企业会计准则解释第 16 号》——关于 单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理， 自 2023 年 1 月 1 日起执行。 证券代码：300550 证券简称：和仁科技 公告编号：2023-048 本次会计政策变更是公司根据财政部相关规定和要求进行的变更，符合相关 法律法规的规定，执行变更后的会计政策能够客观、公允地反映公司的财务状况 和经营成果。本次会计政策变更不会对公司财务状况、经营成果和现金流量产生 重 ...

浙江和仁科技股份有限公司 独立董事关于第四届董事会第二次会议 （本页为《浙江和仁科技股份有限公司独立董事关于第四届董事会第二次会议 相关事项的独立意见》的签署页，无正文） 独立董事签名： 黄 海： 相关事项的独立意见 根据《上市公司独立董事规则》、《上市公司自律监管指引第2号——创 业板上市公司规范运作》和《公司章程》的有关规定，我们作为公司独立董 事，对公司第四届董事会第二次会议相关事项进行了审议，并仔细阅读了公司 提供的相关资料。现基于独立判断立场，发表独立意见如下： 一、关于对关联方占用资金情况和对外担保的独立意见 1、截止2023年6月30日，公司控股股东不存在占用公司资金的情况，也不 存在以前年度发生并累计至2023年6月30日的违规关联方占用资金情况。 2、截止 2023 年 6 月 30 日，公司未发生对外担保的情况，也不存在以前年 度发生并累计至 2023 年 6 月 30 日的其他任何形式的对外担保情况。 二、关于公司2023年半年度募集资金存放与实际使用情况的独立意见 经核查，公司编制的《2023 年半年度募集资金存放与使用情况的专项报告》 内容真实、准确、完整、不存在虚假记录、误导性陈述 ...

根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和深圳证券交易所印发的 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（深证上 〔2022〕14 号）的规定，将本公司募集资金 2023 年 1-6 月存放与使用情况专项说明如下。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可（2020）1243 号文核准，并经深圳证券交易所同 意，本公司由主承销商海通证券股份有限公司采用非公开发行的方式，向特定对象发行人民 币普通股（A 股）股票 25,862,558 股，发行价为每股人民币 19.61 元，共计募集资金 507,164,762.38 元，坐扣承销和保荐费用 7,547,169.81 元后的募集资金为 499,617,592.57 元，已由主承销商海通证券股份有限公司于 2020 年 9月 30日汇入本公司募集资金监管账户。 另减除申报会计师费、律师费、证券登记费等与发行权益性证券直接相关的新增外部费用 3,297,983.47 元 ...